Detalhe da pesquisa
1.
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
N Engl J Med
; 387(8): 692-703, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833805
2.
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.
Ophthalmology
; 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38336282
3.
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
JAMA
; 329(5): 376-385, 2023 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36749332
4.
ASSESSMENT OF FLUORESCEIN ANGIOGRAPHY NONPERFUSION IN EYES WITH DIABETIC RETINOPATHY USING ULTRAWIDE FIELD RETINAL IMAGING.
Retina
; 42(7): 1302-1310, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344528
5.
Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH.
Ophthalmology
; 128(11): 1592-1603, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989683
6.
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
Ophthalmology
; 127(9): 1201-1210, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402554
7.
Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trial.
Clin Trials
; 17(2): 195-201, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984762
8.
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials.
Retina
; 40(6): 1021-1028, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31567817
9.
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
JAMA
; 324(23): 2383-2395, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33320223
10.
Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
Ophthalmology
; 126(1): 87-95, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30096354
11.
PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial.
Retina
; 39(1): 69-78, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29135802
12.
PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?
Retina
; 39(9): 1646-1654, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30807516
13.
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
JAMA
; 321(19): 1880-1894, 2019 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31037289
14.
Evaluation and Care of Patients with Diabetic Retinopathy.
N Engl J Med
; 382(17): 1629-1637, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32320570
15.
Evaluation and Care of Patients with Diabetic Retinopathy. Reply.
N Engl J Med
; 383(5): e31, 2020 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32726546
16.
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
N Engl J Med
; 372(13): 1193-203, 2015 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25692915
17.
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Ophthalmology
; 125(11): 1776-1783, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29980333
18.
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Ophthalmology
; 125(7): 1054-1063, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29525602
19.
CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report.
Retina
; 38(10): 1896-1904, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30234859
20.
Four-Year Visual Outcomes After Intravitreous Aflibercept for Vision-Threatening Complications of Diabetic Retinopathy-Reply.
JAMA
; 329(20): 1796, 2023 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37219555